发布时间 : 星期三 文章纳米激素及相关药物 - 图文更新完毕开始阅读
Cu2O ＋ 2H＋ → 2Cu2＋ ＋ H2O ＋2e－
更易向右进行，更有效地转化成Cu2＋。另外，由纳米金属/聚合物复合材料制成的IUD，不存在金属铜的断裂和脱落而提前取出等问题，可以最大限度地利用金属铜。因此，金属铜的有效利用率可极大提高。
（4）复合材料的自洁功能
金属铜是亲水性物质，现有含铜IUD中金属铜表面直接与宫腔液接触，腐蚀后其表面将变得更粗糙，其亲水性会变得更好，对金属铜在宫腔液中的腐蚀产物有更强的黏附能力，长期使用后其表面聚集大量的沉积物[68]。而新型IUD材料——聚合物基纳米铜复合材料的基体采用的是憎水性聚合物，纳米铜颗粒均匀地分布在聚合物基体中，其与宫腔液接触的绝大部分是憎水性的聚合物基体，虽然在宫腔液中腐蚀放出的二价铜离子后，聚合物表面不会变粗糙，但是对金属铜在宫腔液中腐蚀产生的其他产物的黏附能力仍然很差，因此那些腐蚀产物不会在新型IUD材料表面产生沉积，具有良好的保持表面清洁的能力。
（5）简化含铜IUD的制作工艺
用纳米金属铜/聚合物复合材料来制作含铜IUD，由于其可以释放二价铜离子而增强避孕效果的金属铜与作为含铜IUD支架的聚合物基体复合为一体，加之纳米金属铜/聚合物复合材料具有与作为支架的聚合物基体相似的韧塑性和热加工成型性能，因此只需要制作合适形态的IUD模具，采用热塑性塑料的常规加工方法，就可以一次加工成型而得到商品化的含铜IUD，相比于现有含铜IUD，其制备工艺大大简化。
参 考 文 献
1 国家药典委员会. 中华人民共和国药典（2005版，二部）. 北京：化学工业出版社，2005 2 陈新谦，金有豫，汤光. 新编药物学（第十五版）. 北京：人民卫生出版社，2003 3 徐辉碧，杨祥良. 纳米医药. 北京：清华大学出版社，2004
4 R.H.穆勒著，胡晋红主译. 现代给药系统的理论和实践. 北京：人民军医出版社，2004 5 梅兴国主编. 生物技术药物制剂－基础与应用. 北京：化学工业出版社，2004 6 陆彬. 药物新剂型与新技术（第二版）. 北京：人民卫生出版社，2005 7朱盛山. 药物新剂型. 北京：化学工业出版社，2003 8 潘卫三主编. 新药制剂技术. 北京：化学工业出版社，2004
37
9 Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 1997, 28 (1): 5～24
10 Cleland JL. Protein delivery from biodegradable microspheres. Pharm Biotechnol, 1997, 10 : 1～43
11 Larry R B. Commercial challenges of protein drug delivery. Expert Opinion on drug delivery, 2005, 2 (1): 29～42
12 Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogues. N Engl J Med, 1991, 325 (7): 93～103
13 Minkov, Zozikov, Yaneva, et al. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. Int Urology and Nephrology, 2001, 33 (2): 379～383 14 杨俊杰，王亚敏. 醋酸亮丙瑞林微球. 国外医学药学分册，1998，25 （5）：298～302 15 Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Del Rev, 1997, 28 （1）: 43～70
16 Lee M, Browneller R, Wu Z. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev, 1997, 28 (1): 121～138
17 Woo BH, Kostanski JW, Gebrekidan S, et al. Preparation, characterization and in vivo evaluation of 120-day poly (D,L-lactide) leuprolide microspheres. J Control Release, 2001, 75(3): 307～315
18 冯岚，郭健新，平其能. 亮丙瑞林缓释微球的研究. 中国新药与临床杂志，2004，23 （10）：680～683
19 Fisker S, Kaal A, Montini M，et al. Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR). Eur J Endocrinol, 1997, 136 (1): 61～66
20 Stewart PM, Stewart SE, Clark PM，et al. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf), 1999, 50 (3): 295～299
21 Ayuk J, Stewart SE, Stewart PM, et al. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf), 2004, 60 (3): 375～381
22 Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog
38
(Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab, 1995，80 (11): 3267～3272
23 DongZhi Hou, ChangSheng Xie, KaiJin Huang, et al. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials, 2003, 24（10）: 1781～1785
24 侯冬枝，谢长生，朱长虹. 米非司酮固体脂质纳米粒的性状研究. 中国医药工业杂志，2004，35 （10）：602～605
25 Hou Dong-Zhi, Xie Chang-Sheng, Zhu Chang-Hong. Influence of ratios of drug to lipid on the characteristics of solid lipid nanoparticles containing mifepristone. Journal of China Pharmaceutical University, 2005, 36 (1): 22～36
26 侯冬枝，谢长生. 米非司酮固体脂质纳米粒冷冻干燥性能的研究. 中国药科大学学报，2004，35（5）：413～416
27 Livesidege GC. Drug nanocrystals for improed drug delivery. Int Symp Control Rel Bioact Mater, 1996, 23: 74～81
28 Wei Liu, Yaoliang Zhu Huabing Chen, Xiangliang Yang. Characteristics and transdermal drug delivery of triamcinolone-acetonide-acetate loaded solid lipid nanoparticles carbomer gel. J Chin Pharm Sci, 2005, 14 (1): 18～24
29 Kim MK, Chung SJ, Lee MH, et al. Targeted and sustained delivery of hydrocortisone to normal and stratum corneum-removed skin without enhanced skin absorption using a liposome gel. J Control Release, 1997, 46（3, 2）: 243～251
30 Zheng Y, FuLu MY, Qiu Y, et al. Enzymatic degradation of leuprolide in rat intestinal mucosal homogenates. Pharm Der Technol, 1999, 4 (4): 539～544
31 Adjei P, Sundberg D, Miller J, et al. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res, 1992, 9 (2): 244～249
32 郭健新，平其能，董隽，等. 壳聚糖包衣脂质体对α-糜蛋白酶降解醋酸亮丙瑞林的保护作用. 中国药学杂志，2005，40 （1）： 47～50
33 郭健新，平其能，董隽，等. 醋酸亮丙瑞林脂质体及壳聚糖包衣脂质体经肠道及Caco-2细胞转运机制. 药学学报，2005，40 （1）： 65～70
34 Bajusz S, Csernus VJ, Janaky T, et al. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res, 1988, 32 (6): 425～435 35 Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of
39
tumorigenesis. Peptides. 1999, 20(10): 1247～1262
36 Grohganz H, Tho I, Brandl M. Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix. Eur J Pharm Biopharm, 2005, 59(3): 439～448 37 Merviel P, Najas S, Campy H, et al. Use of GNRH antagonists in reproductive medicine. Minerva Ginecol. 2005, 57 (1): 29～43
38 Grohganz H, Schl?fli O, Rischer M, et al. Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions. J Pharm Biomed Anal, 2004, 34(5): 963～969
39 Sarlikiotis W, Bauer H, Rischer M, et al. Injection solutions with increased stability comprising LHRH antagonists, surfactants and a hydroxycarboxylic acid. PCT Int Appl 2003
40 Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 1997, 28 (1): 5～24
41 Goldspiel BR, Kohler DR. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer. DICP, 1991, 25 (7-8): 796～804
42 Bauer H, Deger W, Sarlikiotis W, et al. Sustained release salts of pharmaceutically active peptides and their production. PCT Int 2000
43 Reissmann T, Hilgard P, Harleman JH, et al. Treatment of experimental DMBA induced mammary carcinoma with cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. J Cancer Res Clin Oncol, 1992, 118(1): 44～49
44 Engel J, Reissmann T, Riethmuller-Winzen H, et al. Means for treating prostate hypertrophy and prostate cancer with cetrorelix, alone or in combination with other agents. PCT Int 1998 45 Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, et al. Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate, 1994, 24(2): 84～92
46 Gonzalez-Barcena D, Buenfil MV, Procel EG, et al. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, cetrorelix (SB-75). Eur J Endocrinol, 1994, 131: 286～292
47 Csernus VJ, Szende B, Schally AV. Release of peptides from sustained delivery systems (microcapsules and microparticles) in vivo. A histological and immunohistochemical study. Int J
40